Patent ID: 8790689

Claim:
A transdermal dosage form comprising an active agent component having a proximal surface and a distal surface; an adverse agent component disposed distally of the active agent component, having a proximal surface and a distal surface and comprising naltrexone; and a barrier interposed between the active agent component and the adverse agent component, having a proximal surface and a distal surface and that is permeable to a solvent selected from the group consisting of water, ethanol, ether, and mixtures thereof; wherein one or more channels extend from the proximal surface of the active agent component to the distal surface of the barrier such that the channels terminate prior to the proximal surface of the adverse agent component and the barrier is in fluid communication with the distal surface of the active agent component at each channel; wherein the active agent component comprises fentanyl dispersed in a pressure-sensitive adhesive selected from the group consisting of acrylates, polyisobutylenes, silicone polymers, and mixtures thereof; wherein air is disposed in one or more channels; wherein before being tampered with the adverse agent does not substantially diffuse into the channels and after being tampered with at least a portion of the adverse agent passes into one or more channels; and wherein the ratio of active agent to adverse agent absorbed when the dosage form is exposed to a liquid is from about 10:1 to about 2:1.